Analysts Set Vyome Holdings, Inc. (NASDAQ:HIND) PT at $15.00

Shares of Vyome Holdings, Inc. (NASDAQ:HIND) have received a consensus rating of “Hold” from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $15.00.

HIND has been the subject of a number of recent analyst reports. Litchfield Hills Research initiated coverage on Vyome in a report on Monday, May 4th. They set a “buy” rating for the company. Zacks Research raised shares of Vyome to a “hold” rating in a report on Wednesday, May 6th. Finally, Weiss Ratings upgraded shares of Vyome from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st.

Vyome Price Performance

Vyome stock opened at $2.06 on Wednesday. The firm has a market capitalization of $14.46 million, a P/E ratio of -0.17 and a beta of 1.49. Vyome has a one year low of $1.75 and a one year high of $18.60. The business has a fifty day moving average price of $2.20 and a 200-day moving average price of $2.40.

Vyome (NASDAQ:HIND) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter. The company had revenue of $0.03 million during the quarter. Sell-side analysts expect that Vyome will post -0.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Vyome stock. Geode Capital Management LLC purchased a new stake in shares of Vyome Holdings, Inc. (NASDAQ:HIND) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned approximately 0.21% of Vyome at the end of the most recent reporting period. Institutional investors and hedge funds own 22.06% of the company’s stock.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.